Erasca is a clinical-stage biopharmaceutical company developing precision oncology therapies aimed at cancers driven by the RAS/MAPK signaling pathway. Its pipeline centers on targeted small-molecule programs designed to address mutations and resistance mechanisms common in hard-to-treat solid tumors. The company focuses on scientifically defined patient populations rather than broad chemotherapy approaches.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -31 | — |
| Q2 2025 | 0 | — | -33.9 | — |
| Q3 2025 | 0 | — | -30.6 | — |
| Q4 2025 | 0 | — | -29.1 | — |
| Q1 2026 | 0 | — | -183.4 | — |
| Q2 2026 | 0 | — | -44.1 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Option Care Health, Inc. (OPCH), Synaptics Incorporated (SYNA), Iridium Communications Inc. (IRDM), The Chefs' Warehouse, Inc. (CHEF), BillionToOne, Inc. (BLLN), GDS Holdings Limited (GDS)